Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.

ABSTRACT:

Background

To meet the demand for effective and affordable inactivated polio vaccines (IPVs), a reduced dose, aluminium hydroxide (Al(OH)₃)-adjuvanted IPV vaccine was developed (IPV-Al, Picovax®) and evaluated in clinical trials. The present trial is an extension of two previous trials (a primary and a booster trial). The aim was to evaluate the persistence of seroprotective antibodies (poliovirus type-specific antibody titre ≥ 8) in 4-year-old children who previously received IPV-Al as primary and booster vaccine doses and to determine the potential booster response and safety profile of an additional dose of IPV-Al.

Methods

Children participating in the two previous trials were invited to receive one additional dose of IPV-Al at 4 years of age (2.5 years after t

SUBMITTER: Saez-Llorens X 

PROVIDER: S-EPMC9488130 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature